ANI launches authorized Brethine generic
ANI Pharmaceuticals is introducing terbutaline sulfate tablets, in 2.5mg and 5mg dosage strengths.
The product is an authorized generic of Brethine.
Terbutaline sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.
The product has a market value of approximately $11 million, according to IQVIA data. Prior to ANI’s launch, there was only one supplier of the product in the U.S. market, according to the company.
"ANI continues to successfully execute on our strategy of re-commercializing products from our portfolio of acquired discontinued ANDAs and NDAs. Terbutaline sulfate is our seventh generic product introduction in 2018.” ANI president and CEO Arthur Przybyl said, in a statement.
The product is an authorized generic of Brethine.
Terbutaline sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.
The product has a market value of approximately $11 million, according to IQVIA data. Prior to ANI’s launch, there was only one supplier of the product in the U.S. market, according to the company.
"ANI continues to successfully execute on our strategy of re-commercializing products from our portfolio of acquired discontinued ANDAs and NDAs. Terbutaline sulfate is our seventh generic product introduction in 2018.” ANI president and CEO Arthur Przybyl said, in a statement.